Equities

Philogen SpA

Philogen SpA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)19.85
  • Today's Change-0.10 / -0.50%
  • Shares traded8.23k
  • 1 Year change+11.83%
  • Beta0.2961
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7586102
Total Receivables, Net11115.32
Total Inventory2.251.921.30
Prepaid expenses------
Other current assets, total0.280.230.20
Total current assets8999108
Property, plant & equipment, net262321
Goodwill, net------
Intangibles, net1.251.220.95
Long term investments------
Note receivable - long term2.79----
Other long term assets--2.991.66
Total assets119126133
LIABILITIES
Accounts payable7.806.355.83
Accrued expenses1.171.000.54
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.891.761.81
Other current liabilities, total1.861.683.44
Total current liabilities131112
Total long term debt131415
Total debt151616
Deferred income tax0.242.150.34
Minority interest------
Other liabilities, total2.710.961.03
Total liabilities292828
SHAREHOLDERS EQUITY
Common stock5.735.735.73
Additional paid-in capital100106120
Retained earnings (accumulated deficit)(11)(15)(21)
Treasury stock - common(4.84)----
Unrealized gain (loss)0.00----
Other equity, total0.531.261.05
Total equity9198105
Total liabilities & shareholders' equity119126133
Total common shares outstanding404041
Treasury shares - common primary issue0.320.200
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.